当前位置: X-MOL 学术Semin. Thromb. Hemost. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Fibrinolytic Alterations in Sepsis: Biomarkers and Future Treatment Targets
Seminars in Thrombosis and Hemostasis ( IF 5.7 ) Pub Date : 2021-04-20 , DOI: 10.1055/s-0041-1725096
Julie Brogaard Larsen 1 , Anne-Mette Hvas 1, 2
Affiliation  

Sepsis is a life-threatening condition which develops as a dysregulated immune response in the face of infection and which is associated with profound hemostatic disturbances and in the most extreme cases disseminated intravascular coagulation (DIC). In addition, the fibrinolytic system is subject to alterations during infection and sepsis, and impaired fibrinolysis is currently considered a key player in sepsis-related microthrombus formation and DIC. However, we still lack reliable biomarkers to assess fibrinolysis in the clinical setting. Furthermore, drugs targeting the fibrinolytic system have potential value in sepsis patients with severe fibrinolytic disturbances, but these are still being tested in the preclinical stage. The present review provides an overview of key fibrinolytic changes in sepsis, reviews the current literature on potential laboratory markers of altered fibrinolysis in adult sepsis patients, and discusses future perspectives for diagnosis and treatment of fibrinolytic disturbances in sepsis patients.



中文翻译:

脓毒症中的纤维蛋白溶解改变:生物标志物和未来治疗目标

脓毒症是一种危及生命的病症,其发展为面对感染时免疫反应失调,并与严重的止血障碍有关,在最极端的情况下会导致弥散性血管内凝血 (DIC)。此外,纤溶系统在感染和脓毒症期间会发生变化,纤溶受损目前被认为是脓毒症相关微血栓形成和 DIC 的关键因素。然而,我们仍然缺乏可靠的生物标志物来评估临床环境中的纤维蛋白溶解。此外,针对纤维蛋白溶解系统的药物在患有严重纤维蛋白溶解障碍的脓毒症患者中具有潜在价值,但这些药物仍处于临床前阶段。本综述概述了脓毒症中关键的纤维蛋白溶解变化,

更新日期:2021-04-21
down
wechat
bug